Fermenta Biotech Declines 5.29%: Quarterly Setbacks and Market Reaction

Feb 15 2026 11:00 AM IST

Share Via

Fermenta Biotech Ltd’s stock closed the week at Rs.310.90, down 5.29% from Rs.328.25 the previous Friday, underperforming the Sensex which declined 0.54% over the same period. The week was marked by a sharp quarterly earnings decline and a negative financial trend downgrade, which weighed heavily on investor sentiment and share price performance.

Key Events This Week

Feb 9: Q3 FY26 results reveal stalled growth and margin contraction

Feb 10: Sharp quarterly decline confirmed amid negative financial trend

Feb 11-13: Stock stabilises with minor fluctuations amid broader market weakness

Feb 13: Week closes at Rs.310.90, down 5.29%

Week Open

Rs.328.25

Week Close

Rs.310.90

-5.29%

Week High

Rs.328.25

vs Sensex

-4.75%

Feb 9: Quarterly Results Reveal Growth Momentum Stalls

Fermenta Biotech reported its Q3 FY26 results on 9 February, signalling a sharp stall in growth momentum. The company’s net sales for the quarter ended December 2025 declined 12.21% year-on-year to ₹137.36 crores, a reversal from the robust 22.51% growth recorded over the nine-month period. Operating profit margin contracted sharply to 18.17%, the lowest in recent quarters, with PBDIT falling to ₹24.96 crores. Net profit after tax dropped to ₹14.19 crores, with earnings per share (EPS) declining to ₹4.39. This marked deterioration in profitability metrics raised immediate concerns about the sustainability of the company’s earlier growth trajectory.

Feb 10: Negative Financial Trend Confirmed Amid Sharp Quarterly Decline

The following day, 10 February, further analysis confirmed a negative financial trend for Fermenta Biotech. The company’s financial trend score plummeted from a positive 22 to a negative -13 over the last three months, reflecting deteriorating operational efficiency and margin pressures. The stock price reacted accordingly, falling 5.25% to close at Rs.310.35 on heavy volume of 123,990 shares, signalling investor caution. Despite a strong nine-month profit after tax growth of 27.34% to ₹54.08 crores, the quarterly contraction overshadowed earlier gains and prompted a downgrade in the company’s Mojo Grade to Sell, with a current Mojo Score of 38.0.

Feb 11-13: Stabilisation Amid Market Volatility

Following the sharp decline, Fermenta Biotech’s stock showed signs of stabilisation over the next three trading sessions. On 11 February, the share price edged up 0.32% to Rs.311.35 on relatively low volume, while the Sensex gained a modest 0.13%. The stock continued to inch higher on 12 February, rising 0.47% to Rs.312.80 despite the Sensex retreating 0.56%, indicating some resilience. However, on 13 February, the stock slipped 0.61% to close at Rs.310.90, as the broader market weakened sharply with the Sensex falling 1.40%. The week ended with the stock down 5.29%, significantly underperforming the Sensex’s 0.54% decline.

Date	Stock Price	Day Change	Sensex	Day Change
2026-02-09	Rs.327.55	-0.21%	37,113.23	+1.04%
2026-02-10	Rs.310.35	-5.25%	37,207.34	+0.25%
2026-02-11	Rs.311.35	+0.32%	37,256.72	+0.13%
2026-02-12	Rs.312.80	+0.47%	37,049.40	-0.56%
2026-02-13	Rs.310.90	-0.61%	36,532.48	-1.40%

Key Takeaways from the Week

Negative Quarterly Performance: The December 2025 quarter marked a significant reversal for Fermenta Biotech, with net sales declining 12.21% and operating margins compressing to 18.17%. This sharp contraction contrasts with the strong nine-month growth, signalling emerging challenges.

Financial Trend Downgrade: The company’s financial trend score dropped from +22 to -13, reflecting deteriorating profitability and operational efficiency. This shift was accompanied by a downgrade to a Sell rating and a Mojo Score of 38.0, indicating increased caution among investors.

Stock Underperformance: The stock declined 5.29% over the week, significantly underperforming the Sensex’s 0.54% fall. The sharp drop on 10 February coincided with the earnings release and negative trend confirmation, highlighting the market’s reaction to the disappointing results.

Balance Sheet Strength: Despite earnings pressure, Fermenta Biotech maintains a conservative debt-to-equity ratio of 0.29 times, providing financial flexibility to manage current headwinds and potential recovery initiatives.

Conclusion: Navigating a Challenging Phase

Fermenta Biotech Ltd’s week was dominated by a sharp quarterly earnings decline and a consequential downgrade in its financial trend and analyst rating. The 5.29% weekly share price fall, significantly steeper than the Sensex’s 0.54% drop, reflects investor concerns over the sustainability of growth and margin pressures. While the company’s nine-month performance and strong balance sheet offer some reassurance, the immediate outlook remains cautious as the firm seeks to arrest the recent decline and restore operational momentum. Market participants will be closely monitoring upcoming quarters for signs of recovery within the competitive Pharmaceuticals & Biotechnology sector.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE